REGMF (RemeGen Co) Gross-Profit-to-Asset % : 28.28% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. RemeGen Co's annualized Gross Profit for the quarter that ended in Dec. 2024 was $218.9 Mil. RemeGen Co's average Total Assets over the quarter that ended in Dec. 2024 was $774.2 Mil. Therefore, RemeGen Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 28.28%.

RemeGen Co Gross-Profit-to-Asset % Historical Data

The historical data trend for RemeGen Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Gross-Profit-to-Asset % Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

33.21

9.42

14.07

24.56

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial								10.23	10.53	17.87	20.06	28.28

Competitive Comparison of RemeGen Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, RemeGen Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

RemeGen Co Gross-Profit-to-Asset % Calculation

RemeGen Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	187.806	/	( (774.242	+	755.218)	/ 2 )
	=	187.806	/	764.73
	=	24.56 %

RemeGen Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	218.928	/	( (793.215	+	755.218)	/ 2 )
	=	218.928	/	774.2165
	=	28.28 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

RemeGen Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

09995:Hong Kong REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.